In conclusion, the combination of sorafenib and fluvastatin significantly inhibited cellular proliferation and promoted apoptosis in HCC by inhibiting the TLR4-activated NF-κB and MAPK pathways. The gene discussed is TLR4; the disease is hepatocellular carcinoma.